Advertisement Allergan acquires Aczone gel from QLT - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Allergan acquires Aczone gel from QLT

Allergan Sales, a wholly-owned subsidiary of Allergan, and QLT USA, a wholly-owned subsidiary of QLT, have announced the completion of Allergan's acquisition of QLT's Aczone gel 5% product, a topical treatment for acne vulgaris.

As previously announced, Allergan paid approximately $150 million for all assets relating to Aczone gel 5%. Allergan expects to launch Aczone gel 5% in the fourth quarter of 2008 in the US and Canada.

David Pyott, chairman of the board and CEO of Allergan, said: “We are pleased with the opportunity to grow our franchise in medical dermatology where there is a continuous need for new treatment options and strong growth potential.”